Nexstim Oy, a Helsinki, Finland-based medical device company commercializing non-invasive brain diagnostic and therapy technologies, has received a €2m equity financing.
The investment was made by new investor Capricorn Health-tech Fund NV, which joined existing investors HealthCap, LSP (Life Sciences Partners), Sitra and Finnish Industry Investment Ltd, as well as Lundbeckfond Ventures and Ilmarinen in the current €13.4m round.
To date, the company has raised over €30m.
Founded in 2000 and led by CEO Richard Karroum, Nexstim develops Navigated Brain Stimulation (NBS) – non-invasive, image-guided transcranial magnetic stimulation (TMS) – for brain diagnostics and therapy.
In conjunction with the financing, Els Hubloux, Senior Investment Manager, Capricorn Venture Partners, will join the company’s Board of Directors.